Table 4.

New respiratory medication prescriptions from phase 1 to phase 2

	Persistent Chronic Bronchitis– (n = 1,260)	Resolved Chronic Bronchitis (n = 153)	New Chronic Bronchitis (n = 126)	Persistent Chronic Bronchitis+ (n = 126)	Overall P Value
SABA	10.5*	12.9*	27.2†	12.9	<0.0001
SAMA	2.0*†‡	5.1	6.0	4.6	<0.0001
SABA/SAMA	6.5*†‡	6.4	12.1	13.6	<0.0001
LABA	1.7†‡	1.9	3.8	2.3	0.001
ICS/LABA	6.6*†‡	14.7	19.5	19.4	<0.0001
ICS	2.9†	3.8	5.3	7.6	0.029
OCS	1.4†	2.6	2.3	6.1	0.003
LAMA	5.8*†‡	16.5	14.9	14.8	<0.0001

Definition of abbreviations: ICS = inhaled corticosteroids; LABA = long-acting β-agonist; LAMA = long-acting muscarinic antagonist; OCS = oral corticosteroids; persistent chronic bronchitis+ = subjects positive at phase 1/positive at phase 2 for chronic bronchitis; persistent chronic bronchitis– = subjects negative at phase 1/negative at phase 2 for chronic bronchitis; SABA = short-acting β-agonist; SAMA = short-acting muscarinic antagonist.

Values are expressed as a percentage of the group value.

^*P < 0.05 compared with new chronic bronchitis.

^†P < 0.05 compared with persistent chronic bronchitis+.

^‡P < 0.05 compared with resolved chronic bronchitis.